Imunon (DB:CBO) - Prezzo delle azioni, notizie e analisi

CBO Panoramica delle azioni

Imunon, Inc. è una società di biotecnologie in fase clinica, impegnata nello sviluppo di immunoterapie e vaccini per il trattamento del cancro e delle malattie infettive. Maggiori dettagli

CBO analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 22% all'anno per i prossimi 3 anni

Ha meno di 1 anno di pista di cassa

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

+ 3 più rischi

Imunon, Inc. Concorrenti

Medigene

XTRA:MDG1

€22.6m

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€1.4m

4SC

DB:VSC

€49.1m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Imunon
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.66
Massimo di 52 settimane	US$3.70
Minimo di 52 settimane	US$0.44
Beta	2.13
1Variazione di 1 mese	-24.57%
Variazione a 3 mesi	-40.00%
Variazione di 1 anno	-6.38%
3Variazione a 3 anni	-93.02%
Variazione a 5 anni	-96.42%
Variazione dall'IPO	-99.94%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	CBO	DE Biotechs	DE Mercato
7D	1.5%	-0.7%	-0.02%
1Y	-6.4%	-17.2%	8.2%

Ritorno vs Industria: CBO ha superato il German Biotechs che ha restituito -17.2 % nell'ultimo anno.

Rendimento vs Mercato: CBO ha avuto una performance inferiore al mercato German che ha registrato un rendimento 8.2 % nell'ultimo anno.

Volatilità dei prezzi

Is CBO's price volatile compared to industry and market?
CBO volatility
CBO Average Weekly Movement	9.5%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di CBO è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di CBO è diminuita da 35% a 10% nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1982	33	Stacy Lindborg	imunon.com

Imunon, Inc. è una società di biotecnologie in fase clinica, impegnata nello sviluppo di immunoterapie e vaccini per il trattamento del cancro e delle malattie infettive. Il programma clinico principale dell'azienda è IMNN-001, un'immunoterapia a base di DNA per il trattamento localizzato del cancro ovarico, in fase di sviluppo clinico di Fase II. I suoi prodotti in fase preclinica includono IMNN-101, un vaccino di richiamo COVID-19; IMNN-102 per il trattamento del virus di Lassa; e IMNN-201, un vaccino contro l'antigene tumorale Trp2 nel melanoma.

Imunon, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Imunon con la sua capitalizzazione di mercato?
CBO statistiche fondamentali
Capitalizzazione di mercato	€9.65m
Guadagni(TTM)	-€18.68m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.6x

Rapporto P/E

CBO è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
CBO Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$1.67m
Profitto lordo	-US$1.67m
Altre spese	US$17.78m
Guadagni	-US$19.45m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.34
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato CBO nel lungo periodo?

Vedi performance storica e confronto

CBO Panoramica delle azioni

Analisi del rischio

Imunon, Inc. Concorrenti

XTRA:MDG1

€22.6m

XTRA:CNW

€6.5m

XTRA:T5O

€1.4m

DB:VSC

€49.1m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Recent updates

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

New major risk - Financial position

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New major risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

New major risk - Share price stability

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Full year 2022 earnings released: US$5.03 loss per share (vs US$3.83 loss in FY 2021)

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Third quarter 2022 earnings released: US$0.87 loss per share (vs US$0.94 loss in 3Q 2021)

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

First half 2022 earnings released: US$2.86 loss per share (vs US$4.26 loss in 1H 2021)

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings released: US$1.82 loss per share (vs US$1.29 loss in 1Q 2021)

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Full year 2021 earnings released: US$3.83 loss per share (vs US$10.08 loss in FY 2020)

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Celsion Corporation announced that it expects to receive $28.5 million in funding

Third quarter 2021 earnings released: US$0.063 loss per share (vs US$0.24 loss in 3Q 2020)

Celsion Corporation Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform